University of Chicago’s Polsky Center for Entrepreneurship has formed microbiome-focused Avnovum Therapeutics, BiomeSense, Covira and Oxalo Therapeutics over the past year.
University of Chicago (UChicago)’s Polsky Center for Entrepreneurship has highlighted the founding of four US-based biotech spinouts focused on microbiome-based applications over the past year.
The companies include Avnovum Therapeutics, which is working on microbial peptides that help vitalise fungal microbiomes by preventing infection and virulence, and BiomeSense, which is developing an automated sensor that evaluates the microbial composition of air and water.
Avnovum Therapeutics builds on work by Eugene Chang, an associate section chief for research at the Department of Medicine focused on research in gastroenterology, hepatology and nutrition.
BiomeSense has been publicised previously, having received $250,000 from University of Chicago’s George Shultz Innovation Fund in June 2018.
The spinout was co-founded by Jack Gilbert, a professor of surgery at University of Chicago Medicine, together with Savas Tay, associate professor at the Institute of Molecular Engineering, and Kevin Honaker, a graduate from the Booth School…
